Kendall R. Ickes

Kendall Ickes focuses her practice on transactional matters in the intellectual property and technology space. Ms. Ickes advises clients from a wide range of industries, including financial services and private equity, with a strong focus on matters in the health care, pharmaceuticals and biotechnology sectors. She also provides intellectual property and technology-related support on M&A and secured financing transactions.

Her significant representations include:

Life Sciences

• Alcon Inc. in its $355 million acquisition of the U.S. commercialization rights to SIMBRINZA from Novartis AG
• Alnylam Pharmaceuticals, Inc. in its $2.8 billion co-development and co-commercialization agreement with Roche Holding AG to develop and commercialize its hypertension drug Zilebesiran
• Catalent, Inc. in its acquisition by Novo Holdings, the holding and investment company for the Novo Nordisk Foundation, at an enterprise value of $15.5 billion
• CerSci Therapeutics, Inc. in its acquisition by ACADIA Pharmaceuticals Inc. for $53 million upfront and contingent payments of $887 million
• Exelixis, Inc. in its exclusive clinical development and option agreement with Sairopa B.V. for a monoclonal antibody drug targeting cancer cells
• MorphoSys AG in its $2.9 billion acquisition by Novartis AG and simultaneous sale of all worldwide rights to the antibody drug tafasitamab to Incyte Corporation
• Pfizer Inc. in connection with various research and development financing arrangements
• POINT Biopharma Global, Inc. in its $1.4 billion acquisition by Eli Lilly and Company

Other Representative Transactions

• ByteDance Ltd. in connection with various matters related to the TikTok app
• Coty Inc. in its strategic partnership with KKR & Co. Inc., including a $1 billion investment to be made in two tranches ($750 million and $250 million) in Coty through the sale of convertible preferred shares to KKR
• Dell Technologies Inc. in its $4 billion sale of Boomi, Inc. to Francisco Partners and TPG Capital
• Massachusetts Mutual Life Insurance Company in the $2.35 billion sale of its retirement plan business to Empower Retirement, LLC
• OceanSound Partners, LP in its strategic investment in Lynx Software Technologies and various other transactions
• Purolite Corporation in its $3.7 billion sale to Ecolab Inc.
• Spotify Technology S.A. in its acquisition of Bill Simmons’ The Ringer
• Tula Life, a probiotic skincare company, in its acquisition by Proctor & Gamble